WO1990001957A1 - Medicament, procede de traitement de maladies chez l'homme a l'aide d'un tel medicament, ainsi que procede et dispositif de production et de conservation associes - Google Patents

Medicament, procede de traitement de maladies chez l'homme a l'aide d'un tel medicament, ainsi que procede et dispositif de production et de conservation associes Download PDF

Info

Publication number
WO1990001957A1
WO1990001957A1 PCT/US1989/002456 US8902456W WO9001957A1 WO 1990001957 A1 WO1990001957 A1 WO 1990001957A1 US 8902456 W US8902456 W US 8902456W WO 9001957 A1 WO9001957 A1 WO 9001957A1
Authority
WO
WIPO (PCT)
Prior art keywords
medicinal drug
water
medicinal
drug
disease
Prior art date
Application number
PCT/US1989/002456
Other languages
English (en)
Inventor
Moisey Dobruskin
Original Assignee
Moisey Dobruskin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/340,268 external-priority patent/US4957493A/en
Application filed by Moisey Dobruskin filed Critical Moisey Dobruskin
Publication of WO1990001957A1 publication Critical patent/WO1990001957A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood

Definitions

  • My invention relates to a medicinal drug for treating hu ⁇ man diseases and to a method of treating human diseases ha ⁇ ving viral and bacterial causes.
  • the invention also relates to methods and devices for producing the medicinal drug and preserving its medicinal a ⁇ ttivity.
  • my invention deals with the medicinal drug for and the method of treat ⁇ ment of a human with acquired immunodeficiency syndrom / as well as other viral and bacterial diseases.
  • Medicinal drugs and method of treatment of viral and bac ⁇ terial diseases are widely J ⁇ iown and perform their medical action in many different ways. They possess different strengths and have different mechanisms of action. There are also many . various methods and devices for producing such medicinal drugs, and for preservation of them in medicinalnically active condi ⁇ tion. It is to be understood that it is desirable to propose further medicinal drugs and method of treatments with higher medicinal action and lower side effects.
  • My new method of treatment of humans having viral and bacterial as well as some other diseases includes admini ⁇ stration of an effective disease treatment amount of the above specified medicinal drug.
  • the medicinal drug of my invention When the medicinal drug of my invention is administered to a human in the course of treatment, the high negative electric potential of the pathogen membranes is neutralized, the pathogens are deprived of their bioelectro nductive pro ⁇ perties, the pathogen membranes are destroyed and cannot be restored, the reproduction of the pathogens and their circu ⁇ lation in the organism in terminated, and immuno-defensi- ve forces of the organism are enhanced.
  • the excited water atoms and molecules (the latter preferably anodically pola ⁇ rised), and the positive ions of the metal are attracted to the outer membranes of the pathogenic microorganisms.
  • a method and a device for producing the new medicinal drug include steps and means for subjecting water to the action of a high energy physical field such as to electronically excite atoms and molecules of water, and for conducting a process which produces positive ions of a metal which are contained in the water with the excited atoms and molecules. These two steps can be performed separately or simultaneo ⁇ usly with one another.
  • a container for preserving medicinal., action of my new medicinal drug.
  • my new container In addition to a wall which limits an inner chamber for accommodating my new medicinal drug.
  • my new container has means which act through the wall for passively preventing the decrease in the excitation and the electric charge of the medicinal substance or active ⁇ ly supplying an additional energy to the latter.
  • FIGS. 1 and 2 schematically show a pathogen cell before the action and during the action of my new medicinal drug
  • FIGS.3-15 schematically show several devices for producing the new medicinal drug
  • FIGS.16 and- 17 show my new me ⁇ thod of treatment of humans with the new medicinal drug
  • FIGS.18-30 schematically show several containers for preserving the new medicinal substance in accordance with the- invention.
  • the medicinal drug includes a plurality of electronically excited atoms and molecules of water H-0, H, 0-, produced under the action of a high energy physical field. It also includes positive ions of metals such as Ag, Cu, Au t Pt and other, produced for example by electrolysis.
  • the water molecules can be a ⁇ odically polarized.
  • the positive atom ions of metals can be also excited.
  • the excited and polarized water molecules and the exci ⁇ ted water atoms together with the positive ions of metal are attracted to the outer membrane of pathogenic micro ⁇ organisms (viruses, bacteria, etc), which membrane has a negative charge and contains polarized molecules.
  • pathogenic micro ⁇ organisms viruses, bacteria, etc
  • the positive ions of metal preferable in excited condition, passes through the holes in the membrane together with the excited water atoms and molecules into the cell. They surround the citoplasmic membrane of the cell so as to inhibit and stop the enzyme- producing vital function of the citoplasmic membrane and x the cell nucleous.
  • the cell is eventually destroyed. Only the joint action of the excited atoms and molecules of water with the positive ions of metals can achieve the above described destruction of the pathogen cell in fast, efficient and irreversible manner.
  • the medicinal drug of the invention does not produce any chemical action. Ins ⁇ tead it acts by electronic interaction with the pathogen cells, and more particularly by non-valent electronic act ⁇ ions. Due to the nature of healthy cell membranes which are different from those of the pathgen cell membranes, the medicinal drug of my invention does not affect the heal ⁇ thy cells and therefore is substantially non-toxic to the latter.
  • the atoms and molecules of water can be electronically excited so as to be in a metastable excitement condition.
  • the electronically excited water atoms and molecules maintain their excited condition over a substantially long time period.
  • the atoms and molecules of water in the medicinal drug can be excited to oscillate with frequencies which correspond to the frequencies of the Shuman row, namely 8, 14, 20, 26...Hz., which correspond to the oscillating frequencies of healthy cells.
  • the healthy cells become stronger, which the pathogen cells are bioelectro- magnetically weakened.
  • the atoms and molecules of water are excited so as to become -predominantly positive. Thereby the postive charges of the water and the metal ions sup ⁇ port each other and have a prolonged life span.
  • the medicinal drug of the invention can be easily adjus ⁇ ted to provide a selected medicinal action or in other words to attack desired pathogen types.
  • the water atoms and molecules must be excited with higher excitation energy, and the positive ions of metal must be contained in a lower concentration.
  • the medicinal drug has a higher bactericidal property when the excitation energy of the water atoms and molecules is lower, while the concentration of the positive metal ions is higher.
  • a virici ⁇ dal formulation of the medicinal drug can include the water ' atoms and molecules excited with the energy of 10-30 Kev and positive silver ' , ions in concentration substantially 20 mg/1, while the bactericidal formulations can use the excitation energy for water atoms and molecules 1-2 KeV and the silver - ions concentration of 40 mg/1.
  • the medicinal drug of the invention can additionally include another medicinal substance or substances having specific action to certain diseases.
  • they further enhance the heelingproperties of the drug.
  • at least a portion of the other medicinal substance, for example its active radicals, is also electronically excited. This significantly increases the efficiency of the specific action of the other medicinal substance.
  • the inventive medi ⁇ cinal drug including only the electronically excited atoms and molecules of water in combination with the above men ⁇ tioned other medicinal substance in excited state.
  • the other medicinal substances can be herbs, such as for example: Chaparral used for treating sores, infections, insect and animal bites, irritations and inflammations of skin; devils claw used in cases of arthritis and reumathis- mus, and as a blood cleanser and purifier; .chinacea used as a blood cleanser, bactericidal substance and immunosti- mulator, etc.
  • the new inventive medicinal drug is an electro- biologically active drug which can be used for treatment of viral, bacterial and other diseases, including such new and dangerous diseases as acquired immunodeficiency syndrome AIDS, ARC, AIDS carrier , sexually transmit ⁇ ted diseases, etc. It can also be used for prophylaxis such diseases and for stimulation of immune forces of the organism. It is strong anti-viral, anti-bacterial and immuno-stimulating drug. It has a differential toxicity in that it is substantially non-toxic for healthy human cells, while is selectively toxic for pathogen cells having triggerr ⁇ ng sites in their membrane and underlying ATP.
  • the medicinal drug can be used together with oxygen for external uti ⁇ lization.
  • Oxygen contributes to fast emission of high ener ⁇ gy photons by excited atoms. Together with the oxygen the viricidal and bactericidal action .of the medicinal drug considerably increases and performs momentary action.
  • Oxygen is produced by adding hydrogen peroxide with concentration of 1: 1000, as well as K Mn 0., ozone, etc.
  • the medicinal drug must have pH within the range between 7.0 and 7.3 to provide its optimal ac ⁇ tion. Due to its excitation and electrical charge, the medi ⁇ cinal drug must be preserved in special containers which prevent the decrease of the above parameters, as will be explained in detail hereinbelow.
  • the medicinal substance can be administered internal ⁇ ly such as orally and parenterally, and externally in form of drops, capsules, sprays. It can also be administered rec- tally. When it is used in capsules, they dissolve inside the body and release the medicinal drug. In the case of the oral use, the dosage acts during 4-5 hours. Its metal ingredients leave the body with urine and feces.
  • the medicinal drug in form of eye drops can be used with the excitation energy from 1 to 12 KeV and the concen ⁇ tration of copper ions 20 mg/1, gold ions 100 mg/1, platinum ions 100 mg/1 .
  • the medicinal drug for gargling can be used with the excitation energy between 12and 15 KeV and the concentration of silver ions 40 mg/1, copper ions 1 mg/1, gold ions lg/1, platinum ions 1 g/1.
  • the medical drug can be used with the excitation energy between 1 and 12 KeV and concentration of silver ions 30 mg/1, copper ions 1 mg/1, gold ions 2-5 g/1, platinum ions 2-4 g/1.
  • the medicinal substance for exterior app ⁇ lication in form of inhalation , it can be used with the excitation energy between 12 and 25 KeV with the concentration of silver ions 20 mg/1, gold ions lg/1, plati ⁇ num ions lg/ 1.
  • the medicinal drug with copper ions is used only as spray with copper concentration of 1 mg/1.
  • the bactericidal utilization of the inventive medicinal drug is illustrated for profilaxis and treatment of gonorrhea.
  • the medicinal drug is used with the energy of excitation bet ⁇ ween 5 and 8 KeV and the concentration of silver ions 40 mg/1.
  • the drug can be used fo spraying of urine passage or vagina, for treatment it can be used orally or pa- renterally and accompanied by the above spraying.
  • the medicinal drug of the invention can be produced by new methods and devices described hereinbelow.
  • the distance from the ultrsonic transducer to the anode has to be equal to a wavelength of the ultrasound or its integer multiple, with recommended frequency 20-24 kHz and power 100-120 db.
  • the power control is performed as shown in FIG.5 by a control device including a monitor for electrolyser 6, an ultrasound generator 7;., a laser power supply.8 and a battery or ano ⁇ ther electrical source.
  • the device of FIG.9 has positive and negative electro ⁇ des 29 and 30, an ultrasonic transducer 31, a generator of superhigh frequency oscillations 32.
  • the unit 32 produces the physical f eld and can have a range of 6-7 mm wave ⁇ length.
  • the device of FIG. 10 includes a high voltage or high frequency electrolyser with modulation with high frequen ⁇ cies of the Shuman row and with utltasonic field.
  • Positive electrode 31 can be of a desired metal (silver, copper, gold, platinum), negative elect ' ride 32 can be the same or from stainless steel.
  • the ultrsonic transducer can have a fre ⁇ quency of 23 kHz, and an insulating material is 34.
  • a metal electrode 35 produces a positive electric field, while a metal electrode 36 produces a negative electricf field.
  • FIG.12 shows a device with a light pump up. It can have a pulse lamp xenon quartz envelope flushtube of blue-green light. Photones of green light produce the pump-up or inverse populating of molecules of water and metal. Pulses are in the range 1-26 Hz. Quantum jump or electron transfer from one orbit to another occurs here, with discharge of an energy.
  • the flushtube is identified as 37, while a casing of the device is 38.
  • FIG. 12 shows an electrolysis in the field of a dis ⁇ orienting device which produces a relatively powerful time variant magnetic f eld to eliminate the action of the Earth magnetic field. The rate of flux chages in the field is made variable over the range of 1-26 magnetic pulses per sec.
  • the inductive coil is 42 and the plastic housing is 41. The device produces excited water atoms and molecules , and po ⁇ sitive metal ions, to produce the inventive medicinal drug.
  • FIGS. 13 and 14 show a device which can be used for spraying the medicinal drug. It has a distributing and char ⁇ ging cone 54 and a pulverizing metal tip 55 for a flow of the medicinal drug. In this device the medicinal drug is additionally electrically charged.
  • a nozzle of pulverizer can be composed of one pole electret as identified with 57, or two pole electret as identified with 58.
  • the device can be used with a mask 53, to confine and introduce the sprayed medicinal sibstance.
  • FIGS. 15 shows a device diagram with a micro ⁇ processor 69, a timer 70, a modulator 71, a high voltage.” (5- 10 kV) and/or high frequency (20- 40 kHz) generator 72, and voltage generator ( 200 V DC) 73. Due to the special bioelectronic nature of the medicament ⁇ nal ..drug its is advisable to take measures for preserving its bioelectronic action over a sufficient time. Special containers for this purpose are proposed in accordance with the invention, as shown in FIGS. 18-30.
  • the container 101 . in FIG. 18 has a wall limiting an inner chamber for accommodating the drug and having a plu ⁇ rality of layers.
  • An inner layer 102 is composed of a dialectric such as polyethylene. It directly sepatates the medicinal drug from other layers to form a phase sepa ⁇ rating partition. Molecules of this layer are polarized from the outer side by electrostatic field of a layer 106 and from the inner side by the field of the drug. The pola- fcized molecules or dipoles 105 of the layer 102 are oriented in a certain fashion.
  • the layer 106 is composed of a dialec ⁇ tric which during its manufacture is impregnated with nega ⁇ tive static electricity.
  • the electrostatic energy of the layer 106 is transformed into the energy of charging of the drug by induction process.
  • the layer 106 is an energy generator.
  • a layer 104 is an insulator and can be composed of polyesther with specially polarized oriented molecules.
  • a layer 103 is formed as a Faraday cage or metal cage which acreens or protects the whole container from the action of external electromagnetic fields (electrostatic charge, radi ⁇ ation , light, heat, etc. ) .
  • the wall of the container of FIG. 19 has five layers.
  • the layers 106 and 107 are energy-generating layers.
  • a layer 107 is composed of dialectric impregnated during its manufac ⁇ ture with positive static electricity.
  • the electrostatic ene ⁇ rgy of the layers 106,107 are here added and doubled and induces the drug.
  • These layers are thin ion-exchange mem ⁇ branes based on high molecular compositions which pass nega ⁇ tively and positively charged ions.
  • the wall of the container of FIG. 20 has three la ⁇ yers including the Faraday cage supplied with static energy from a battery 108. Here the metal cations are additionally charged by induction.
  • the wall of the container of FIG.21 also has three layer, and a screen layer 103 is supplied with energy of external electromagnetic field from a convertor 109.
  • the circuit of the convertor is tuned to a nearby po- wrrful radiostation.
  • the wall of the container of FIG.22 has seven layers, of which three layers are formed as a Fara ⁇ day cage. They form screens which not only protect the drug from external fields but also accumulate the energy of the latter. By means of a diode 110 and condensor 11 this ener ⁇ gy is concentrated on the inner screen 103 and from there induced into the drug..
  • the innermost layer 103 can be of lead to shield the radiation
  • the middle layer 103 can be of copper * to screen from external electric field
  • the outer ⁇ most layer 103 can be of iron to screen from magnetic action.
  • the container of FIG. 23 has small spheres from fluo- roplastic, polyethylene, etc, which are freely accommodated in it. Before use the container is shaken. Under the action of friction the spheres are electrified and give a powerful additional positive charge for superactivation of the drug.
  • the container of FIG. 24 has a piezoelectric convertor 114 for converting mechanical energy into electrical with hig potential of 5-10 kV. Needles are located inside the drug for flowing electric charges into the latter to provide its activation. The convertor is actuated manually by a user.
  • the container of FIG. 25 has a lurality of hair or spirals on the inner surface of the layer 102, composed of readily electrofyable plastic. During shaking the drug rubs against them and is strongly electrified and obtains an additional charge.
  • FIGS. 26,27 each show containers with two spherical members A,B with elastic wall 16 formed as in FIGS.18-23.
  • the members are connected by a thin pipe with a Faraday cones 117 of a readily electrifyable material.
  • FIG.28 shows a container with a hermetically closed plastic pack 118 with a thermogenerator. The pack and the main wall are connected by elements 120. When the container is squeezed, the drug is electrified by friction and simultaneously heated by the known thermogenerator.
  • 29 shows a container with hermetically closed pack containing hydrigen peroxide 119 and perforating meedle 121.
  • the needle pierces the pack ' , and the hydrigen peroxide is mixed with the drug to add the action of oxygen to the latter.

Landscapes

  • Health & Medical Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Le médicament décrit, qui sert à traiter des maladies en particulier d'origine virales et bactériennes chez l'homme, contient des atomes et des molécules d'eau excités électroniquement, qui détruisent au moins partiellement les membranes des cellules pathogènes, ainsi que des ions métalliques positifs qui pénètrent dans les membranes partiellement détruites pour inhiber les fonctions vitales des cellules pathogènes. Un tel médicament est produit par application d'un champ physique à énergie élevée destiné à exciter les atomes et les molécules d'eau et à produire par voie électrolytique des ions métalliques positifs, et peut être stocké dans des récipients assurant la conservation de son excitation et de sa charge électrique.
PCT/US1989/002456 1988-08-29 1989-05-19 Medicament, procede de traitement de maladies chez l'homme a l'aide d'un tel medicament, ainsi que procede et dispositif de production et de conservation associes WO1990001957A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23826788A 1988-08-29 1988-08-29
US238,267 1988-08-29
US07/340,268 US4957493A (en) 1987-11-30 1989-04-19 Method of and device for preserving biological and medical action of substances based on electrical charge and/or state
US340,268 1989-04-19

Publications (1)

Publication Number Publication Date
WO1990001957A1 true WO1990001957A1 (fr) 1990-03-08

Family

ID=26931497

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/002456 WO1990001957A1 (fr) 1988-08-29 1989-05-19 Medicament, procede de traitement de maladies chez l'homme a l'aide d'un tel medicament, ainsi que procede et dispositif de production et de conservation associes

Country Status (2)

Country Link
AU (1) AU4058789A (fr)
WO (1) WO1990001957A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0433067A2 (fr) * 1989-12-13 1991-06-19 Edip Prof. Dr. Büyükkoca Agent immunomodulateur non spécifique et son procédé de préparation
WO2000012134A1 (fr) * 1998-09-01 2000-03-09 Wetling John F Composition traitee par voie electrique et utilisation d'une telle composition
EP1027098A1 (fr) * 1997-05-29 2000-08-16 Kevin R. Orton Substance electriquement activee et son procede de fabrication
WO2002013900A1 (fr) * 2000-08-16 2002-02-21 Violetta Silfver Procede et dispositif permettant de traiter notamment le col de l'uterus
US6488032B1 (en) 1997-05-29 2002-12-03 Kevin R. Orton Method of providing cosmetic/medical therapy
FR2855757A1 (fr) * 2003-06-03 2004-12-10 Eric Georges Andre Pichot Procede de fabrication d'agents therapeutiques "neutralisants" par creation sur un substrat-substance de sites therapeutiques en miroir de ceux de l'agents pathogene grace a des secouements effectues entre eux
US6920884B2 (en) 1997-05-29 2005-07-26 Kevin Orton Method of providing cosmetic/medical therapy
EP1810683A1 (fr) * 2004-09-27 2007-07-25 Hoshizaki Denki Kabushiki Kaisha Immunopotentiateur et ses procede et appareil de fabrication

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147775A (en) * 1976-10-06 1979-04-03 Schwartz Stephen H Antiseptic composition
US4474748A (en) * 1979-09-26 1984-10-02 Johnson & Johnson Medicaments potentiated with phenyl alkanols
US4540403A (en) * 1984-07-02 1985-09-10 Alza Corporation Parenteral dispensing system with programmable drug administration
US4822339A (en) * 1984-12-06 1989-04-18 Controlled Release Technologies, Inc. Therapeutic agent delivery system and method

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147775A (en) * 1976-10-06 1979-04-03 Schwartz Stephen H Antiseptic composition
US4474748A (en) * 1979-09-26 1984-10-02 Johnson & Johnson Medicaments potentiated with phenyl alkanols
US4540403A (en) * 1984-07-02 1985-09-10 Alza Corporation Parenteral dispensing system with programmable drug administration
US4822339A (en) * 1984-12-06 1989-04-18 Controlled Release Technologies, Inc. Therapeutic agent delivery system and method

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0433067A2 (fr) * 1989-12-13 1991-06-19 Edip Prof. Dr. Büyükkoca Agent immunomodulateur non spécifique et son procédé de préparation
EP0433067A3 (en) * 1989-12-13 1991-09-25 Edip Prof. Dr. Bueyuekkoca A non-specific immunomodulating agent and a process for its production
EP1027098A1 (fr) * 1997-05-29 2000-08-16 Kevin R. Orton Substance electriquement activee et son procede de fabrication
EP1027098A4 (fr) * 1997-05-29 2001-03-28 Kevin R Orton Substance electriquement activee et son procede de fabrication
US6488032B1 (en) 1997-05-29 2002-12-03 Kevin R. Orton Method of providing cosmetic/medical therapy
US6920884B2 (en) 1997-05-29 2005-07-26 Kevin Orton Method of providing cosmetic/medical therapy
WO2000012134A1 (fr) * 1998-09-01 2000-03-09 Wetling John F Composition traitee par voie electrique et utilisation d'une telle composition
WO2002013900A1 (fr) * 2000-08-16 2002-02-21 Violetta Silfver Procede et dispositif permettant de traiter notamment le col de l'uterus
US6939336B2 (en) 2000-08-16 2005-09-06 Violetta Silfver Method and device for treating inter alia the cervix
FR2855757A1 (fr) * 2003-06-03 2004-12-10 Eric Georges Andre Pichot Procede de fabrication d'agents therapeutiques "neutralisants" par creation sur un substrat-substance de sites therapeutiques en miroir de ceux de l'agents pathogene grace a des secouements effectues entre eux
EP1810683A1 (fr) * 2004-09-27 2007-07-25 Hoshizaki Denki Kabushiki Kaisha Immunopotentiateur et ses procede et appareil de fabrication
EP1810683A4 (fr) * 2004-09-27 2008-12-10 Hoshizaki Electric Co Ltd Immunopotentiateur et ses procede et appareil de fabrication

Also Published As

Publication number Publication date
AU4058789A (en) 1990-03-23

Similar Documents

Publication Publication Date Title
Sunnen Ozone in medicine: overview and future directions
Pakhomov et al. Current state and implications of research on biological effects of millimeter waves: a review of the literature
CN101107039A (zh) 递送治疗性金属离子、合金以及盐的方法
AU2006252145B2 (en) Synergetic drug delivery device
US7291314B2 (en) Activated water apparatus and methods
JPH09511752A (ja) 心筋症と多発性硬化症の治療用のインビボ殺微生物剤としての電気加水分解済み食塩水
EP1355734B1 (fr) Dispositif et procede de production d'eau activee
Choi et al. Plasma bioscience for medicine, agriculture and hygiene applications
US6506403B1 (en) Treatment patch
Jani et al. Ozone therapy: the alternative medicine of future
EP2455032B1 (fr) Dispositif de libération de médicament
WO1990001957A1 (fr) Medicament, procede de traitement de maladies chez l'homme a l'aide d'un tel medicament, ainsi que procede et dispositif de production et de conservation associes
Lupu et al. Cold atmospheric plasma jet effects on V79-4 cells
Ryan et al. Overview of plasma technology used in medicine
CN220043735U (zh) 产生冷空气等离子体的设备及产生电晕冷空气等离子体的设备
JP4024227B2 (ja) 電位治療器と電位治療器用波形整形器
US20220401748A1 (en) Cold air plasma generating apparatus
RU2726611C2 (ru) Способ инициации гибели опухолевых клеток 5-аминолевулиновой и янтарной кислотами и ВЧ- и СВЧ-энергией волнового излучения
RU2723885C2 (ru) Способ инициации гибели опухолевых клеток натриевой солью гематопорферина, янтарной кислотой и ВЧ- и СВЧ-энергией волнового излучения
JPH07508671A (ja) パルス化された磁気誘導のための方法および装置
EP0965350A1 (fr) Procede d'excitation de matiere photosensible
RU2726608C2 (ru) Способ инициации гибели опухолевых клеток натриевой солью гематопорферина и ВЧ- и СВЧ-энергией волнового излучения
RU2726609C2 (ru) Способ инициации гибели опухолевых клеток гидроксиалюминием трисульфофталоцианина, янтарной кислотой и ВЧ- и СВЧ-энергией волнового излучения
RU2724326C2 (ru) Способ инициации гибели опухолевых клеток натриевыми солями хлорина-e6, хлорина-p6 и пурпурина-5 и ВЧ- и СВЧ-энергией волнового излучения
RU2723490C2 (ru) Способ инициации гибели опухолевых клеток гидроксиалюминия трисульфофталоцианином и аскорбиновой кислотой и ВЧ- и СВЧ-энергией волнового излучения

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR DK FI JP KR NO SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE